Antibe Therapeutics Inc.
ATE
株式のランク
#31788
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
株価
$0.21483059
最終同期: 2024-05-07
時価総額
$11.13M
変化（1日）
0.34%
変化（1年）
-0.36%
国
CA
取引 Antibe Therapeutics Inc. (ATE)
カテゴリー
Healthcare
Antibe Therapeutics Inc.（ATE）の株価履歴
終値の最高値: $0.22 （2025-04-01）
終値の最安値: $4.78 （2014-10-01）
終値の最安値: $4.78 （2014-10-01）
Antibe Therapeutics Inc. の株価履歴（2014 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2025 | -0.02% |
| 2024 | -64.79% |
| 2023 | 73.56% |
| 2022 | -33.35% |
| 2021 | -82.11% |
| 2020 | -6.13% |
| 2019 | 60.42% |
| 2018 | 70.25% |
| 2017 | -45.71% |
| 2016 | 86.85% |
| 2015 | -71.73% |
| 2014 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $100.56 | -21.41% |
US
|
|
| $93.07 | -2.95% |
IE
|
|
| $297.13 | -23.49% |
US
|
|
| $44.47 | -57.18% |
US
|
|
| $47.05 | -17.88% |
DE
|
